Erbitux (Cetuximab) - Biological Cancer Therapy
Key Data:
Drug (Brand/Generic)
Erbitux (cetuximab, C225)
Company/Licensee
ImClone Systems Inc/ Bristol-Myers Squibb/ Merck-Serono
Therapy Class
Anti-neoplastic agent
Product Description
Anti-EGFR MAb
Current Indication
Metastatic colorectal cancer, locally advanced squamous cell carcinoma of the head and neck
Market Sector
Oncology
Development Status
Approved
